Unichem Lab's Ghaziabad unit gets EIR from USFDA
New Delhi: Drug firm Unichem Laboratories said its facility at Ghaziabad has received establishment inspection report (EIR) from the US health regulator.
The inspection was conducted by United States Food and Drug Administration (USFDA) in April 2018, Unichem Laboratories said in a filing to BSE.
"Unichem's formulation manufacturing facility at Ghaziabad has received an EIR from USFDA indicating closure of inspection," it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd